Implantica's Groundbreaking Study Shows Promising Results for RefluxStop™ Treatment in Germany
Implantica AG, a leader in medtech innovation, has recently announced the publication of its remarkable findings from the largest real-world study in Germany concerning its flagship product, RefluxStop™. Conducted at Germany's premier reflux center and published in the journal Surgery Open Science, this study sheds light on the outcomes experienced by patients suffering from gastroesophageal reflux disease (GERD).
The research, led by the esteemed Priv.-Doz. Dr. Thorsten G. Lehmann, showcased a compelling retrospective analysis involving 79 patients followed over a period of up to 17 months. The findings revealed a drastic reduction in the necessity for proton pump inhibitor (PPI) medication, plummeting from a staggering 94.9% pre-surgery to a mere 2.5% post-surgery follow-up. This substantial shift highlights the RefluxStop™ device's potential to significantly enhance the quality of life for those afflicted with GERD.
The data collected provides clear evidence of both safety and efficacy with RefluxStop™, evidenced by astonishing improvements in the GERD-HRQL (Gastro-Esophageal Reflux Disease - Health-Related Quality-of-Life) scores, which saw a 100% improvement in median scores and a notable 92.4% mean improvement among participants. This is particularly noteworthy as almost half of the participants had pre-existing conditions that typically complicate surgical outcomes, such as large hiatal hernias or histories of failed anti-reflux procedures.
Dr. Peter Forsell, CEO of Implantica, expressed deep appreciation for the collaborative effort of independent surgeons willing to document and share the results of RefluxStop™. He noted, "Priv.-Doz. Dr. Lehmann's findings reaffirm the tremendous effectiveness we have seen at multiple surgical centers across Europe. With over 1,000 patients treated with RefluxStop™ in the past five years, these results mark a significant milestone in redefining GERD treatment for millions globally."
The RefluxStop™ device presents an innovative solution to GERD by not merely addressing symptoms, but directly correcting the anatomical cause. Unlike traditional surgical options that involve encircling the esophagus—a procedure often linked with adverse effects such as difficulty swallowing and unable to belch—the RefluxStop™ restores the integrity of the lower esophageal sphincter without exerting pressure. It reconstructs the essential components of the anti-reflux barrier, optimizing the body's natural defenses against acid reflux.
Implantica is committed to advancing the understanding and treatment of GERD through substantial research and development efforts. Their strategic focus encompasses eHealth technologies that monitor various health parameters and supports the remote management of treatment, which stands to enhance patient care and outcomes significantly. This innovative approach could catalyze substantial changes in how acid reflux is treated, with the potential to improve life quality for countless patients through its patented eHealth monitoring and wireless technology platforms.
As the medical community continues to favor data-driven approaches, studies like Dr. Lehmann's reinforce the growing acknowledgment of RefluxStop™ as a possible game-changer in anti-reflux surgery. As the findings reach healthcare providers worldwide, they could lead to broader adoption of this revolutionary treatment method.
For additional information about Implantica and its innovative products, please visit www.implantica.com.
The research, led by the esteemed Priv.-Doz. Dr. Thorsten G. Lehmann, showcased a compelling retrospective analysis involving 79 patients followed over a period of up to 17 months. The findings revealed a drastic reduction in the necessity for proton pump inhibitor (PPI) medication, plummeting from a staggering 94.9% pre-surgery to a mere 2.5% post-surgery follow-up. This substantial shift highlights the RefluxStop™ device's potential to significantly enhance the quality of life for those afflicted with GERD.
The data collected provides clear evidence of both safety and efficacy with RefluxStop™, evidenced by astonishing improvements in the GERD-HRQL (Gastro-Esophageal Reflux Disease - Health-Related Quality-of-Life) scores, which saw a 100% improvement in median scores and a notable 92.4% mean improvement among participants. This is particularly noteworthy as almost half of the participants had pre-existing conditions that typically complicate surgical outcomes, such as large hiatal hernias or histories of failed anti-reflux procedures.
Dr. Peter Forsell, CEO of Implantica, expressed deep appreciation for the collaborative effort of independent surgeons willing to document and share the results of RefluxStop™. He noted, "Priv.-Doz. Dr. Lehmann's findings reaffirm the tremendous effectiveness we have seen at multiple surgical centers across Europe. With over 1,000 patients treated with RefluxStop™ in the past five years, these results mark a significant milestone in redefining GERD treatment for millions globally."
The RefluxStop™ device presents an innovative solution to GERD by not merely addressing symptoms, but directly correcting the anatomical cause. Unlike traditional surgical options that involve encircling the esophagus—a procedure often linked with adverse effects such as difficulty swallowing and unable to belch—the RefluxStop™ restores the integrity of the lower esophageal sphincter without exerting pressure. It reconstructs the essential components of the anti-reflux barrier, optimizing the body's natural defenses against acid reflux.
Implantica is committed to advancing the understanding and treatment of GERD through substantial research and development efforts. Their strategic focus encompasses eHealth technologies that monitor various health parameters and supports the remote management of treatment, which stands to enhance patient care and outcomes significantly. This innovative approach could catalyze substantial changes in how acid reflux is treated, with the potential to improve life quality for countless patients through its patented eHealth monitoring and wireless technology platforms.
As the medical community continues to favor data-driven approaches, studies like Dr. Lehmann's reinforce the growing acknowledgment of RefluxStop™ as a possible game-changer in anti-reflux surgery. As the findings reach healthcare providers worldwide, they could lead to broader adoption of this revolutionary treatment method.
For additional information about Implantica and its innovative products, please visit www.implantica.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.